Pharmacologic interventions for reducing spasticity in cerebral palsy.
D. Patel, и O. Soyode. Indian J Pediatr, 72 (10):
869--872(октября 2005)
Аннотация
Motor function abnormalities are a key feature of cerebral palsy. Spasticity is one of the main motor abnormalities seen in children with cerebral palsy. Spasticity is a velocity dependent increased resistance to movement. While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate. Thus, treatment to reduce spasticity requires careful consideration of various factors. Non-pharmacologic interventions used to reduce spasticity include physiotherapy, occupational therapy, use of adaptive equipment, various orthopedic surgical procedures and neurosurgical procedures. Pharmacologic interventions used for reducing spasticity in children with cerebral palsy reviewed in this article include oral administration of baclofen, diazepam, dantrolene and tizanidine, intrathecal baclofen, and local injections of botulinum toxin, phenol, and alcohol.
%0 Journal Article
%1 Patel2005a
%A Patel, Dilip R
%A Soyode, Olufemi
%D 2005
%J Indian J Pediatr
%K Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; Clonidine; Dantrolene; Diazepam; Ethanol; Humans; Infant; Injections, Intramuscular; Spinal; Muscle Relaxants, Central; Spasticity; Neuromuscular Agents; Phenol; Time Factors
%N 10
%P 869--872
%T Pharmacologic interventions for reducing spasticity in cerebral palsy.
%V 72
%X Motor function abnormalities are a key feature of cerebral palsy. Spasticity is one of the main motor abnormalities seen in children with cerebral palsy. Spasticity is a velocity dependent increased resistance to movement. While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate. Thus, treatment to reduce spasticity requires careful consideration of various factors. Non-pharmacologic interventions used to reduce spasticity include physiotherapy, occupational therapy, use of adaptive equipment, various orthopedic surgical procedures and neurosurgical procedures. Pharmacologic interventions used for reducing spasticity in children with cerebral palsy reviewed in this article include oral administration of baclofen, diazepam, dantrolene and tizanidine, intrathecal baclofen, and local injections of botulinum toxin, phenol, and alcohol.
@article{Patel2005a,
abstract = {Motor function abnormalities are a key feature of cerebral palsy. Spasticity is one of the main motor abnormalities seen in children with cerebral palsy. Spasticity is a velocity dependent increased resistance to movement. While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate. Thus, treatment to reduce spasticity requires careful consideration of various factors. Non-pharmacologic interventions used to reduce spasticity include physiotherapy, occupational therapy, use of adaptive equipment, various orthopedic surgical procedures and neurosurgical procedures. Pharmacologic interventions used for reducing spasticity in children with cerebral palsy reviewed in this article include oral administration of baclofen, diazepam, dantrolene and tizanidine, intrathecal baclofen, and local injections of botulinum toxin, phenol, and alcohol.},
added-at = {2014-07-19T20:59:33.000+0200},
author = {Patel, Dilip R and Soyode, Olufemi},
biburl = {https://www.bibsonomy.org/bibtex/264da0532269d75b7216213798ba0d178/ar0berts},
groups = {public},
interhash = {a6bb166b986d4360676dbea16270b456},
intrahash = {64da0532269d75b7216213798ba0d178},
journal = {Indian J Pediatr},
keywords = {Administration, Oral; Adrenergic alpha-Agonists; Age Factors; Anti-Infective Agents, Local; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child, Preschool; Clonidine; Dantrolene; Diazepam; Ethanol; Humans; Infant; Injections, Intramuscular; Spinal; Muscle Relaxants, Central; Spasticity; Neuromuscular Agents; Phenol; Time Factors},
month = Oct,
number = 10,
pages = {869--872},
pmid = {16272661},
timestamp = {2014-07-19T20:59:33.000+0200},
title = {Pharmacologic interventions for reducing spasticity in cerebral palsy.},
username = {ar0berts},
volume = 72,
year = 2005
}